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Abstract
Background: Arthropod-borne viruses (arboviruses) are among the most common agents of human febrile illness
worldwide and the most important emerging pathogens, causing multiple notable epidemics of human disease over recent
decades. Despite the public health relevance, little is know about the geographic distribution, relative impact, and risk
factors for arbovirus infection in many regions of the world. Our objectives were to describe the arboviruses associated with
acute undifferentiated febrile illness in participating clinics in four countries in South America and to provide detailed
epidemiological analysis of arbovirus infection in Iquitos, Peru, where more extensive monitoring was conducted.
Methodology/Findings: A clinic-based syndromic surveillance system was implemented in 13 locations in Ecuador, Peru,
Bolivia, and Paraguay. Serum samples and demographic information were collected from febrile participants reporting to
local health clinics or hospitals. Acute-phase sera were tested for viral infection by immunofluorescence assay or RT-PCR,
while acute- and convalescent-phase sera were tested for pathogen-specific IgM by ELISA. Between May 2000 and
December 2007, 20,880 participants were included in the study, with evidence for recent arbovirus infection detected for
6,793 (32.5%). Dengue viruses (Flavivirus) were the most common arbovirus infections, totaling 26.0% of febrile episodes,
with DENV-3 as the most common serotype. Alphavirus (Venezuelan equine encephalitis virus [VEEV] and Mayaro virus
[MAYV]) and Orthobunyavirus (Oropouche virus [OROV], Group C viruses, and Guaroa virus) infections were both observed in
approximately 3% of febrile episodes. In Iquitos, risk factors for VEEV and MAYV infection included being male and reporting
to a rural (vs urban) clinic. In contrast, OROV infection was similar between sexes and type of clinic.
Conclusions/Significance: Our data provide a better understanding of the geographic range of arboviruses in South
America and highlight the diversity of pathogens in circulation. These arboviruses are currently significant causes of human
illness in endemic regions but also have potential for further expansion. Our data provide a basis for analyzing changes in
their ecology and epidemiology.
Citation: Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, et al. (2010) Arboviral Etiologies of Acute Febrile Illnesses in Western South America,
2000–2007. PLoS Negl Trop Dis 4(8): e787. doi:10.1371/journal.pntd.0000787
Editor: Scott B. Halstead, Pediatric Dengue Vaccine Initiative, United States of America
Received March 2, 2009; Accepted July 12, 2010; Published August 10, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This study was funded by the United States Department of Defense Global Emerging Infections Systems Research Program, WORK UNIT NUMBER:
847705.82000.25GB.B0016. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: tad.kochel@med.navy.mil
Introduction
Over the past few decades there has been a global resurgence of
arthropod-borne viral pathogens (arboviruses) worldwide [1,2],
particularly those transmitted by mosquitoes. Despite the public
health relevance, the geographic range, relative impact, and
epidemiologic characteristics associated with arbovirus infection
are poorly described in many regions of the world. Arboviruses are
a heterogeneous group, but those of medical relevance largely
belong to a few virus genera, including Flavivirus, Alphavirus, and
Orthobunyavirus. Prominent examples of emergent arboviruses
include West Nile virus (WNV; Flavivirus) in North America,
Japanese encephalitis virus (JEV; Flavivirus) in Asia, chikungunya
virus (CHIKV; Alphavirus) in the Indian Ocean region and dengue
viruses (DENV; Flavivirus) worldwide. One common feature shared
by many emergent arboviruses is the capacity to expand host and
geographical range, owing in part to the plasticity of the RNA
genome [3]. Some arboviruses have evolved to exploit humans as
their primary reservoir, while others rely on birds or peridomestic
animals, with human infection resulting from spill-over from
zoonotic replication cycles. Human exposure to sylvatic arbovirus
cycles is likely to increase as activities continue to encroach on
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round hot and humid conditions, are well-suited for maintaining
arboviruses with potential to emerge as significant human
pathogens [4]. In the neotropics alone, greater than 145 distinct
arbovirus species have been identified [4], many of which have
already been associated with human illness.
One limitation of conducting surveillance for arboviral diseases
is the generic nature of disease presentation. While severe disease
can result, such as hemorrhagic manifestations (DENV and yellow
fever virus [YFV]) or neurological disease (WNV, JEV, and
Venezuelan equine encephalitis virus [VEEV]), arbovirus infection
typically results in mild to moderate febrile illness [2,5,6].
Particularly early in disease progression, patients commonly
present with undifferentiated febrile illness [5,7] rendering clinical
diagnosis unreliable [8]. In DENV-endemic areas, for example,
diseases caused by co-circulating pathogens have been found to be
often misclassified [8,9]. In light of the lack of distinct clinical
presentation and the diversity of the etiologic agents, laboratory
support has become a critical component of effective surveillance
programs.
The impact on human health in endemic regions and the
potential for broader spread underscore the importance of
improving understanding of arbovirus transmission patterns.
Currently the epidemiological characteristics and geographic
range for many endemic arboviruses in South America are poorly
understood. To begin to address this gap, we established a
laboratory-supported clinic-based study to identify the etiologic
agents associated with undifferentiated febrile illness in sites in
Peru, Ecuador, Bolivia, and Paraguay. Herein we describe the
geographic distribution of distinct arboviruses and their relative
contribution to human febrile illness in these study sites. In
addition, we present the temporal trends and epidemiological
characteristics associated with arbovirus infection in Iquitos, Peru,
a site where more extensive monitoring was conducted.
Methods
Study Locations
In 1990 the U.S. Naval Medical Research Center Detachment
(NMRCD) initiated a clinic-based surveillance program to
determine the etiologies of febrile illness in Iquitos, Peru [10–
12]. In 2000 NMRCD collaborated with local Ministries of Health
to expand the surveillance program into other regions of Peru and
South America, including sites in Ecuador, Bolivia, and Paraguay.
In addition to Iquitos, in 2000 the study was implemented at
regional sites in or near Piura, Cusco, Tumbes, and Yurimaguas,
Peru, as well as Santa Cruz, Bolivia (Figure 1; Table 1). Additional
sites were later added in Concepcio ´n, Magdalena, and Cocha-
bamba (Villa Tunari and Eterazama), Bolivia; Guayaquil,
Ecuador; Asuncio ´n, Paraguay; and La Merced and Puerto
Maldonado, Peru ´. Participants were recruited when reporting
with acute febrile illness to public, private, or military health
facilities in and around these regional centers. Details of the study
sites are described in Table 1. Study sites were selected based
largely on locations in hot and humid climates conducive for
arbovirus transmission, typically situated near or in tropical
rainforest regions. Notable exceptions include Piura, Tumbes,
and Cusco, which are located in coastal desert (Piura and Tumbes)
or highlands (Cusco; Figure 1 and Table 1) regions. It should be
noted that the study staff in Cusco (Hospital Regional) on occasion
attended to participants arriving from surrounding highlands
rainforest regions.
Ethics statement
Study protocols (NMRCD.2000.0006 [Peru], NMRCD.2001.
0002 [Ecuador], NMRCD.2000.0008 [Bolivia], and NMRCD.
2005.0008 [Paraguay]) were approved by the Naval Medical
Research Center Institutional Review Board (Bethesda, MD) in
compliance with all U.S. Federal regulations governing the
protection of human subjects. In addition, the study protocols
were reviewed and approved by health authorities in Peru
(Direccio ´n General de Epidemiologı ´a), Bolivia (Servicio Departa-
mental de Salud, Santa Cruz and Colegio Medico de Santa Cruz),
Ecuador (Ministerio de Salud Publica, Comando Conjunto de la
Fuerzas Armadas, and Escuela de Sanidad in Guayaquil) and
Paraguay (Ministerio de Salud y Bienestar Social and Comite ´d e
E ´tica de Asociacio ´n de Rayos de Sol). Written consent was
obtained from patients 18 years of age and older. For patients
younger than 18 years, written consent was obtained from a parent
or legal guardian. Additionally, written assent was obtained from
patients between 8 and 17 years of age.
Study subjects
Study subjects included patients 5 years of age or older who
presented in outpatient clinics or hospitals with acute, undifferen-
tiated, febrile illness (greater than or equal to 38uC for 7 days
duration or less) along with one or more of the following
symptoms: headache, muscle, ocular and/or joint pain, general-
ized fatigue, cough, nausea, vomiting, sore throat, rhinorrhea,
difficulty breathing, diarrhea, jaundice, dizziness, disorientation,
stiff neck, or bleeding manifestations. Children younger than five
years of age were included if they presented with hemorrhagic
manifestations indicative of dengue hemorrhagic fever (DHF),
including epistaxis, pleural effusion, platelets less than 100,000/ml,
petechiae, or bloody stool or vomit. Exclusion criteria included
fever in excess of seven days or an identifiable focus of infection,
such as sinusitis, pneumonia, acute otitis media, or acute urinary
tract infection. Demographic data, medical history, and clinical
features for each patient were obtained using a standard
questionnaire. In malaria-endemic regions if malaria was suspect-
ed, capillary blood from febrile patients was screened for
Plasmodium spp. by clinic or hospital personnel according to
routine diagnostic procedures at each site. Peripheral blood
samples were screened by microscopic analysis of stained thick
Author Summary
Over recent decades, the variety and quantity of diseases
caused by viruses transmitted to humans by mosquitoes and
other arthropods (also known as arboviruses) have increased
around the world. One difficulty in studying these diseases is
the fact that the symptoms are often non-descript, with
patients reporting such symptoms as low-grade fever and
headache. Our goal in this study was to use laboratory tests
todetermine the causes of suchnon-descript illnesses in sites
in four countries in South America, focusing on arboviruses.
We established a surveillance network in 13 locations in
Ecuador, Peru, Bolivia, and Paraguay, where patient samples
were collected and then sent to a central laboratory for
testing. Between May 2000 and December 2007, blood
serum samples were collected from more than 20,000
participants with fever, and recent arbovirus infection was
detected for nearly one third of them. The most common
viruses were dengue viruses (genera Flavivirus). We also
detected infection by viruses from other genera, including
Alphavirus and Orthobunyavirus.T h i sd a t ai si m p o r t a n tf o r
understanding how such viruses might emerge as significant
human pathogens.
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www.plosntds.org 2 August 2010 | Volume 4 | Issue 8 | e787Figure 1. Map of study sites in Ecuador, Peru, Bolivia, and Paraguay. Capitals of Ecuador (Quito), Peru (Lima), and Bolivia (La Paz) are shown
for reference.
doi:10.1371/journal.pntd.0000787.g001
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infection, malaria-positive patients were subsequently invited to
participate in the NMRCD study, with malaria results recorded
along with symptoms and demographic information.
During the acute phase of illness blood samples were obtained
from each patient, and when possible, convalescent samples were
obtained 10 days to 4 weeks later for serological studies. For
patients older than 10 years of age, up to 15 mL of blood was
collected, and for patients younger than 10 years of age, up to
7 mL of blood was collected. Trained phlebotomists collected
blood samples via arm venipuncture using standard methods and
universal precautions.
Laboratory Procedures
Virus isolation. Acute-phase serum samples were
transported on dry ice to the U.S. NMRCD laboratory in Lima
and stored at 280uC. Serum samples were thawed and diluted
1:10 in Eagle’s minimum essential medium (EMEM) containing
2% heat-inactivated fetal bovine serum and antibiotics (200 U/ml
penicillin and 200 mg streptomycin). African Green Monkey Vero
(37uC) and Aedes albopictus C6/36 (28uC) cell cultures were each
inoculated with 200 ml of the diluted serum in 25 ml flasks. Upon
observation of cytopathic effect (CPE) with a light microscope, or
ten days post-inoculation if no CPE was observed, cells were
removed from the flasks, collected by centrifugation for 10
minutes, and placed on 12-well glass spot-slides for microscopic
examination by standard indirect immunofluoresence assay (IFA).
Viral antigens were detected with hyperimmune mouse ascitic
fluid (HMAF) produced in the NMRCD-Lima laboratory against
the arbovirus isolates listed below, followed by the addition of
fluorescein-conjugated goat anti-mouse IgG, similar to previously
described [11,13,14]. DENV serotypes were identified using
serotype-specific monoclonal antibodies (DENV-1: 15F3,
DENV-2: 3H5; DENV-3: 5D4; DENV-4: 1H10).
Serology. IgM titers were determined by using IgM-capture
enzyme-linked immunosorbant assays (ELISA), as previously
described [15,16]. Briefly, microtiter plates (96-well format) were
coated with anti-human IgM (Tago, Inc., Burlingame, CA) diluted
1:800 in phosphate-buffered saline (PBS) and incubated overnight
at 4uC. Participant serum was diluted 1:100 and incubated in
coated wells for 1 h at 37uC, followed by the addition of viral
antigen and incubation at 37uC for 1 h. Viral antigens were
detected with HMAF (produced by inoculation of mice with the
respective viral strains), followed by horseradish peroxidase-
conjugated goat anti-mouse IgM + IgG (Pierce, Rockford, IL).
Following the addition of ABTS (2,29-azino-bis-[3-
ethylbenzthiazoline-6-sulfonic acid]) colorimetric substrate, plates
were read at 410 nm with a Dynex ELISA MRX Revelation
absorbance reader (Dynex Technologies, Chantilly, VA). All
acute- and convalescent-phase samples were initially screened at
1:100. Previously identified reactive patient sera were used as
positive controls, and normal human serum was used as a negative
control. Samples exceeding the reference cut-off value, calculated
as the mean of seven antibody-negative samples (normal human
serum) plus three standard deviations, were considered IgM-
positive. Positive samples were subsequently re-tested at four-fold
serial dilutions (1:100, 1:400, 1:1600, and 1:6400). The highest
dilution at which the OD still exceeded the cut-off value was
considered the final titer.
Viral antigens for the ELISAs were produced at the NMRCD
laboratory in Lima. Antigens were derived from suckling mouse
brain or from supernatants collected from infected African green
monkey kidney Vero cells inoculated with the following virus
strains: for VEEV, subtype ID strain IQT8131; for Murutucu
Virus (MURV), strain IQT9891; for Caraparu Virus (CARV),
strain IQU1719; for MAYV, genotype D strain TRVL15537; for
Eastern equine encephalitis virus (EEEV), strain VR65, for YFV,
17D strain OBS5926; for Oropouche virus (OROV), strain 172;
Table 1. Febrile illness surveillance study sites.
Location Year
1
No. and
types of centers
2 Alt (m)
Mean annual
temp (uC)
Mean annual
precip. (cm)
Bolivia
Concepcio ´n 2004 1 H 497 24.4 116.3
Magdalena 2004 1 H 193 26.7 140.3
Santa Cruz 2000 2 H 437 24.5 134.6
Cochabamba 2005 2 H, C 265 24.6 585.0
Ecuador
Guayaquil 2003 1 M 4 25.0 108.0
Paraguay
Asuncio ´n 2006 1 P 89 23.2 136.6
Peru
Cusco 2000 1 H 3248 12.3 67.1
Iquitos 2000 13 M, C, H 125 26.1 287.9
La Merced 2001 1 H 751 23.0 237.9
Piura 2000 2 C 49 24.5 6.7
P. Maldonado 2004 3 H, C 265 25.3 226.0
Tumbes 2000 2 C 25 25.2 15.0
Yurimaguas 2000 1 H 179 26.6 207.1
1Year site was added to the study.
2Military (M), Public Hospital (H), Public Health Clinic (C), Private Hospital (P).
doi:10.1371/journal.pntd.0000787.t001
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derived from pooled supernatants from infected Vero cells cultures
of all four serotypes, including DENV-1 West Pac 74, DENV-2
S16803, DENV-3 CH53489, and DENV-4 TVP-360. Prior to
homogenization, antigen preparations were inactivated using
3 mM binary ethylenimine.
RT-PCR. To confirm results from IFA, a subset of acute-
phase serum samples were tested for the presence of pathogen-
specific nucleotide sequences by reverse transcription polymerase
chain reaction (RT-PCR). DENV sequences were first amplified
using pan-DENV primers followed by serotype-specific nested
primers, as described previously [17]. VEEV sequences were
amplified as previously reported in [18] and [12], with primer pair
V8369(+) and V9207B(2) or V9257(2) used to detect VEEV
RNA. MAYV sequences were amplified with primer pairs
7336(+)/8140(2) or 9368(+)/10151(2), similar to primers
described in [19].
Case Definitions. Diagnoses were considered confirmed if
they met any of the following criteria: isolation of virus from the
specimen, virus identification by RT-PCR, or 4-fold or greater
increase in IgM antibody titers between acute and convalescent
samples. Diagnoses were considered presumptive if elevated IgM
titers (positive at dilutions greater than or equal to 1:100) were
detected in the acute or in both acute- and convalescent-phase
samples without a four-fold rise between samples. Participants with
evidence of recent infection by more than one arbovirus are
included in each arbovirus category for which such evidence was
observed, as the etiologic agent could not be definitively identified.
The exception to this was within the Flavivirus genus. Since we
observed significant IgM cross-reactivity between DENV and
YFV antigen (see Results), participants were only considered YFV-
positive by serology in the absence of reactivity to DENV antigen
in the IgM ELISA. In the absence of laboratory evidence of any of
the above pathogens, cases were classified as arbovirus-negative.
Statistical Analyses
Statistical analyses (Chi-square, Fisher’s exact test, and logistic
regression) were performed in R version 2.8 (The R Foundation
for Statistical Computing, Vienna, Austria)[20]. The significance
level was set at a=0.05.
Results
A total of 20,880 participants from study sites in Bolivia,
Ecuador, Paraguay, and Peru were enrolled in the study between
May 2000 and December 2007 (Table 2). A total of 18,201
participants (87.2%; Table 2 were included from Peru, 2,089
(10.0%) from Bolivia, 350 from Ecuador (1.7%), and 240 from
Paraguay (1.1%). More than half (10,739; 51.4%) of participants
were recruited at 13 health clinics or hospitals in and around
Iquitos, Peru. For participants where demographic data was
available, 10,919 were male (52.3%) and 9,915 were female
(47.5%). The median age of participants was 24 (range 0–92
years), with 89.5% between the ages of 6 and 49. In addition to
fever, the most commonly reported symptoms included malaise
(96.7%), headache (92.4%), chills (90.2%), myalgia (81.4%),
arthralgia (76.2%), and hyporexia (75%). A thorough breakdown
of symptomology by etiologic agent will be reported elsewhere
(TJK, unpublished results).
Of the 20,880 cases of febrile illness included, paired acute and
convalescent-phase samples were collected from 13,259 partici-
pants (63.5%), while acute-phase only (without convalescent
samples) were available from 7,621 participants (36.5%; Table 2).
Most participants for whom data was available reported to a
health center within four days following disease onset (15,911/
19,632; 81.0%). A subset of participants (n=9,800; 46.9%) were
screened for malaria by thick smear prior to enrollment. Of these,
584 (6.0%) were found to be positive. Patient samples were
screened for recent infection by members of the Flaviviridae,
Table 2. Total febrile participants, by location and year.
Location 2000 2001 2002 2003 2004 2005 2006 2007 Total
% with paired
samples
Bolivia
Concepcio ´n - - - - 83 78 113 106 380 75.0
Magdalena - - - - 70 66 37 - 173 45.6
Santa Cruz 36 101 43 135 93 121 275 476 1280 25.1
Cochabamba - - - - - 99 93 64 256 32.0
Ecuador
Guayaquil - - - 2 72 134 82 60 350 86.2
Paraguay
Asuncio ´n - - - - - - 18 222 240 48.5
Peru
Piura 1009 404 74 181 65 94 79 78 1984 34.5
Cusco 52 122 133 82 106 95 120 116 826 39.2
La Merced - 182 140 115 43 69 120 105 774 70.6
P. Maldonado - - - - 149 318 153 595 1215 42.1
Iquitos 293 897 2113 1040 2308 1458 1433 1197 10739 76.8
Tumbes 147 237 16 107 214 144 153 193 1211 40.0
Yurimaguas 167 124 35 43 227 184 363 309 1452 82.2
Total 1704 2067 2554 1705 3430 2860 3039 3521 20880 63.5
doi:10.1371/journal.pntd.0000787.t002
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ELISA. Evidence for arbovirus infection was observed in 32.5% of
febrile cases overall (Table 3), varying significantly across locations
(p,0.001) from 9.3% (Cusco) to 39.8% (Iquitos). Of these,
diagnoses were considered confirmed for 4,423 febrile episodes
(21.2%), including 2,862 positive by IFA or RT-PCR (13.7%;
Table 4) with or without accompanying elevated IgM, as well as
1,561 IgM seroconversions (7.5%) without accompanying IFA or
RT-PCR confirmation. No arbovirus co-infections were observed
by IFA. An additional 2,370 cases (11.4%) were classified as
presumptive arboviral infections. Viral isolation and RT-PCR
identification was most successful with participant specimens
collected within the first four days following disease onset. Of the
15,911 participants reporting within four days post-disease onset
(where data was available), 2,456 (15.4%) were IFA-positive for an
arbovirus in the acute sample. For those reporting five days or
more post-onset, only 3.8% (143/3,721) were IFA-positive.
Malaria co-infections
DENV was the most common malaria co-infection, observed
for 11.3% (66/584) of participants reported as malaria-positive,
including 17 DENV-3 isolates and one DENV-1 isolate. The rate
of DENV infection was significantly lower for malaria-positive
participants than for malaria-negative participants (11.3% vs
32.9%; p,0.0001). In contrast, VEEV infection was more
common among malaria-positive participants (7.4%) as compared
to malaria-negative participants (2.7%; p,0.0001). There were no
significant differences between malaria thick smear-positive
participants and thick smear-negative participants for the other
arboviruses studied (data not shown).
Flavivirus
DENV serotypes were the predominant arboviruses detected,
accounting for 26.0% of febrile episodes analyzed (Table 5), based
on virological (2,662 virus isolates or RT-PCR positives, with or
without supporting serology) and serological (1,058 IgM serocon-
versions and 1,700 participants with elevated DENV IgM, without
accompanying positive results by virus isolation or RT-PCR)
evidence. Considerable YFV cross-reactivity was observed for
DENV-positive samples. Based on the 2,662 cases with definitive
DENV diagnosis (IFA or RT-PCR confirmation in the acute
sample), 847 (32.0%) also had IgM reactive to YFV antigen in the
acute or convalescent sample.
DENV-3 was most commonly isolated serotype, accounting for
81.1% (2,159/2,662) of DENV isolates over the course of the
study. In our study, DENV-3 was first detected in sites along the
northern coast of Peru (Piura and Tumbes) in 2000 (Figure 2)
during a large outbreak of dengue fever in the region [21,22],
although DENV-1 and DENV-2 were the most commonly
isolated serotypes during this outbreak. DENV-3 quickly became
the dominant serotype in the northeastern rainforest (Iquitos and
Yurimaguas), with limited DENV-1 co-circulation in the region in
subsequent years (Figure 2). Between 2002 and 2006 little DENV-
2 transmission was observed until DENV-2 emerged in the study
sites in Bolivia and southern Peru (Puerto Maldonado) in 2007
(Figure 2). DENV-4 was rarely detected during the study period,
with only four isolates from study participants. However, more
recently this situation has changed dramatically with the 2008
emergence of DENV-4 in northern Peru [23].
Overall, DENV infection was more common among female
participants than male participants (28.1% vs 25.5%; p,0.0001),
with a statistically significant bias towards older participants
(28.0% of participants 30 or older were DENV-positive as
compared with 25.9% of participants younger than 30;
p=0.001). However, the epidemiology of DENV infection varied
by study site, particularly within Peru. The prevalence of DENV
infection was higher among older participants in Puerto
Maldonado (p=0.01), La Merced (p,0.0001), Piura
(p,0.0001), and Tumbes (p=0.015), while no elevated DENV
prevalence was observed for older participants in Yurimaguas and
Iquitos. In addition, DENV infection was more common among
female participants in Puerto Maldonado (p,0.0001), La Merced
(p,0.0001), and Tumbes (p=0.028), but no statistically significant
difference was observed in Iquitos, Yurimaguas, or Piura.
Other than DENV, the only flavivirus isolated during the course
of the study was YFV, which was isolated from four participants
(Table 4). In addition to the four isolates, serological evidence of
recent YFV infection (without evidence of DENV infection) was
detected in an additional 494 participants, including 143 who
seroconverted between acute and convalescent samples. Overall,
data on prior vaccination was available for 17,816 participants,
10,667 (59.9%) of whom reported having received YF vaccination.
YF vaccine coverage varied widely by study site, ranging from less
than 10% in non-endemic sites along the northern coast of Peru
(Piura and Tumbes) to 59% in Iquitos, 70% in Yurimaguas, and
77% or greater in Cochabamba (Villa Tunari and Eterazama),
Concepcio ´n, Junin, Magdalena, and Puerto Maldonado. Study
participants with evidence of recent YFV infection based on IgM
were significantly more likely than the rest of the overall study
population to have reported receiving YF vaccination within the
previous 6 months (30.0% vs. 6.7%; p,0.0001).
Alphavirus
Recent alphavirus infection was detected for 3.1% (n=645) of
febrile patients (Table 5), including 102 VEEV isolates and 40
Table 3. Percentage of febrile participants with evidence of
recent infection by one or more arboviruses, by location,
2000–2007.
Location Pos Neg %
Bolivia
Concepcio ´n 56 324 14.7
Magdalena 26 147 15.0
Santa Cruz 187 1093 14.6
Cochabamba 78 178 30.5
Ecuador
Guayaquil 109 241 31.1
Paraguay
Asuncio ´n 80 160 33.3
Peru
Piura 480 1504 24.2
Cusco 77 749 9.3
La Merced 174 600 22.5
P. Maldonado 373 842 30.7
Iquitos 4276 6463 39.8
Tumbes 394 817 32.5
Yurimaguas 483 969 33.3
Total 6793 14087 32.5
Arboviruses include DENV serotypes, YFV, VEEV, MAYV, EEEV, OROV, Group C
viruses, and GROV. Full breakdown by virus is provided in Table 5.
doi:10.1371/journal.pntd.0000787.t003
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Flavivirus Alphavirus Orthobunyavirus
Location DENV-1 DENV-2 DENV-3 DENV-4 YFV VEEV MAYV OROV Group C GROV
Bolivia
Concepcio ´n 0 31 2 0 0 020 00
Magdalena 0 0 1 0 0 0 0 0 0 0
Santa Cruz 0 15 19 0 0 0 7 0 0 0
Cochabamba 0 0 6 0 1 6 6 0 0 1
Ecuador
Guayaquil 3 0 24 1 0 0 0 0 0 0
Paraguay
Asuncio ´n 0 04 1 0 0 000 00
Peru
Piura 68 158 22 0 0 0 0 0 0 0
Cusco 0 0 0 0 1 0 3 1 0 0
La Merced 43 0 59 0 0 0 0 0 0 3
P Maldonado 0 39 48 0 1 5 5 1 9 1
Iquitos 66 9 1662 0 1 84 13 16 18 1
Tumbes 45 5 91 3 0 0 0 0 0 0
Yurimaguas 44 1 174 0 0 7 4 0 3 0
Total 269 230 2159 4 4 102 40 18 30 6
doi:10.1371/journal.pntd.0000787.t004
Table 5. Breakdown of arboviruses associated with febrile illness, by location, 2000–2007.
DENV YFV
4 VEEV MAYV OROV
Group C
viruses GROV
5
Location Cnf
1 Prs
2 %
3 Cnf
1 Prs
2 %
3 Cnf
1 Prs
2 %
3 Cnf
1 Prs
2 %
3 Cnf
1 Prs
2 %
3 Cnf
1 Prs
2 %
3 Cnf
1 Prs
2 %
3
Bolivia
Concepcio ´n 20 21 10.8 4 5 2.3 0 1 0.3 3 3 0 0 0.0 0 0 0.0 0 0 0.0
M a g d a l e n a 47 6 . 4 486 . 9 000 . 0 121 . 7 000 . 0 000 . 0 000 . 0
Santa Cruz 58 86 11.3 3 24 2.1 1 4 0.4 10 6 1.3 0 2 0.2 0 2 0.2 0 0 0.0
Cochabamba 10 7 6.6 3 17 7.8 11 7 7.0 10 11 8.2 2 7 3.5 2 3 2.0 1 0 0.3
Ecuador
Guayaquil 55 27 23.4 4 14 5.1 3 5 2.3 1 0 0.3 1 1 0.6 0 3 0.9 0 1 0.3
Paraguay
Asuncio ´n 48 26 30.8 0 5 2.1 0 0 0.0 0 0 0.0 0 0 0.0 0 2 0.8 0 0 0.0
Peru
Piura 300 176 24.0 0 5 0.3 0 1 0.1 0 0 0.0 0 1 0.1 0 0 0.0 0 0 0.0
C u s c o 23 0 . 6 85 0 7 . 0 030 . 4 410 . 6 130 . 5 020 . 2 000 . 0
La Merced 125 33 20.4 3 7 1.3 1 0 0.1 0 2 0.2 0 4 0.5 0 1 0.1 5 2 0.9
P. Maldonado 124 86 17.3 22 61 6.8 15 13 2.3 10 10 1.6 7 11 1.5 19 28 3.9 2 1 0.2
Iquitos 2482 965 32.1 65 121 1.7 204 149 3.3 48 59 1.0 65 115 1.7 84 94 1.7 2 4 0.1
Tumbes 189 181 30.6 8 10 1.5 0 6 0.5 0 0 0.0 0 2 0.2 0 0 0.0 1 0 0.1
Yurimaguas 303 83 26.6 19 24 3.0 15 9 1.7 11 5 1.1 4 7 0.8 16 10 1.8 0 1 0.1
Total 3720 1701 26.0 143 351 2.4 250 198 2.1 98 99 0.9 80 153 1.1 121 145 1.3 11 9 0.1
1Confirmed cases (virus isolation, RT-PCR, or IgM seroconversion).
2Presumptive cases (elevated IgM without 4-fold rise between acute and convalescent).
3Percent of total febrile cases from this location.
4Manyoftheparticipantswith YFV-reactiveserum arelikely dueto recent vaccinationorFlavivirus cross-reactivity,and thusare not reflectiveofnaturalYFV infection(seetext).
5Only limited serologic testing for GROV IgM was performed prior to 2007.
Virus isolates (Table 4) are included with the confirmed diagnoses.
doi:10.1371/journal.pntd.0000787.t005
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extracted, reverse transcribed, amplified, and sequenced. All
sequenced isolates were determined to belong to enzootic subtypes
of the VEE complex, predominately ID Panama/Peru or Peru/
Bolivia genotypes [12,14,24] although there was one ID
Colombia/Venezuela genotype and one IIID subtype virus
identified, both in Iquitos [12]. The majority of VEEV isolates
and seroconversions (234/250; 93.6%) were from patients in
Iquitos, Puerto Maldonado, and Yurimaguas, Peru. In contrast,
MAYV isolates were more prevalent in Bolivia and southeastern
Peru (Table 4). Of all MAYV isolations, 57.5% (23/40) were from
this region, despite representing only 19.8% of all participants in
the study.
EEEV was not isolated from any participant samples during the
course of the study. A subset of participant samples were screened
for EEEV-reactive IgM (n=3,014), with serological evidence for
Figure 2. DENV serotypes circulating in western South America, 2000–2007. DENV serotypes circulation was analyzed based on different
regions, including (A) Ecuador and northwestern Peru (Tumbes and Piura), (B) northeastern and central Peru (Iquitos, Yurimaguas, and La Merced),
and (C) southeastern Peru (Puerto Maldonado) and Bolivia.
doi:10.1371/journal.pntd.0000787.g002
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Unlike the flaviviruses, little serologic cross-reaction (or, alterna-
tively, concurrent infection) was observed among alphaviruses. For
the 72 participants with the most well-defined VEEV infections
(IFA-positive, plus a convalescent sample available for testing), 7
(9.7%) had IgM reactive to MAYV antigen in either the acute or
convalescent sample. For the 24 cases where MAYV was isolated
and a convalescent sample was available for testing, no cross-
reactivity was observed in the VEEV IgM ELISA.
Orthobunyavirus
Arboviruses belonging to the Orthobunyavirus genus of the
Bunyaviridae family accounted for approximately 2.5% of all febrile
cases (Table 5). In total there were 54 orthobunyavirus isolates,
including 30 Group C viruses, 18 OROV isolates, and six GROV
(Table 4). The Group C virus isolates were not definitively
identified; however, based on serological techniques (ELISA and
PRNT), ten were antigenically related to CARV and six were
antigenically related to MURV, while 14 could not be antigen-
ically distinguished. Nearly all Simbu Group (OROV) and Group
C virus isolates were collected from patients reporting to clinics in
Iquitos, Madre de Dios, and Yurimaguas, Peru, while three out of
six GROV isolates were obtained from patients in La Merced,
Peru, in January and February of 2007 (Table 4). As with the
alphaviruses, little serologic cross-reaction was observed within the
Orthobunyavirus genus. For the 24 participants IFA-positive for a
Group C virus and a convalescent sample available, only 2 had
IgM reactive to OROV antigen in either the acute or convalescent
sample (8.3%); for the 12 OROV IFA-positive participants with a
paired convalescent sample, no reactivity with CARV or MURV
antigen was observed.
Incidence rates and epidemiology of arbovirus infection
in Iquitos, Peru
The Iquitos health centers included in this study cover a
geographically stratified area of the city and in 2007 represented
nearly 20% (10 of 55) of civilian public health centers in the
greater urban health network. Based on the populations assigned
to each health center by the local ministry of health (Direccio ´n
Regional de Salud -Loreto), in 2007 clinics included in this study
were designated to serve approximately 43% of the population of
the Iquitos region. Using the population numbers assigned to each
health center by DIRESA-Loreto, we estimated incidence rates for
the most common arboviral infections in Iquitos beginning with
the first full year of the study (Table 6). Over the course of the
study, there were 855.9 acute undifferentiated febrile episodes per
100,000 people per year, peaking during periods of highest dengue
activity (2002 and 2004; Table 6). DENV incidence rates varied
greatly, peaking in 2002 with 554.0/100,000 following the
introduction of DENV-3 and averaging 274.7/100,000 over the
7-year period. The average symptomatic incidence rates for other
predominant arboviruses were 28.1/100,000 for VEEV, 8.5/
100,000 for MAYV, 14.3/100,000 for OROV, and 14.2/100,000
for Group C viruses. Peak transmission rates were observed for
these four viruses between 2004 and 2006, including a previously-
described outbreak of VEEV in 2006 [24].
It should be noted that the incidence rates above only reflect the
participants enrolled in the study. Starting in 2006, demographic
data was collected for those who reported to Iquitos health centers
and fulfilled the inclusion criteria (acute undifferentiated febrile
illness of fewer than 7 days in duration) but declined participation
in the febrile surveillance study. In 2006 and 2007, 3,385 and
3,283 febrile patients, respectively, fitting the case definition were
examined by study personnel, with 43.3% (n=1,433) and 36.5%
(n=1,197) of patients agreeing to provide venous blood samples
for the surveillance program. During these two years, 94.3% of
febrile patients were first screened for malaria by thick smear, with
32.4% of those screened classified as positive. Malaria-negative
patients were significantly more likely to accept participation in the
surveillance study (51.3%; 2,185/4,256) than malaria-positive
patients (9.5%; 193/2,036; p,0.001). Children were significantly
less likely to participate than adults (25.3% of eligible children vs.
44.0% of eligible adults chose to participate; p,0.001).
To begin to describe the epidemiology associated with these
arboviruses in the Iquitos, demographic characteristics of
participants with recent infection by the most common pathogens
– DENV serotypes, VEEV, MAYV, OROV, and Group C viruses
– were compared with the rest of the participating febrile
population in Iquitos. YFV infection, as determined by positive
IgM ELISA, was significantly associated with self-reported recent
YF vaccination (OR 2.30, 95% CI 1.44—3.57); no similar
association was observed for other arboviruses. Thus no further
analyses were conducted for YFV IgM-positive participants.
Overall, male participants were more common than female
(51.4% vs. 48.6%), consistent with the population of Loreto
Department as a whole (51.2% male; p=0.77)[25]. The median
age of study participants was 23 (average 26.1), with the highest
percentage of participants between the ages of 15 and 29. Both
MAYV (p=0.003) and VEEV (p=0.009) infection were signifi-
cantly more common among males, and this effect was only
observed among the older age groups (15 years or older),
suggesting an occupational exposure. A similar trend for higher
prevalence of Alphavirus infection among males was observed in
Yurimaguas and Puerto Maldonado, although these analyses were
limited by small sample size. Group C virus infection was more
common in males in these three sites, although the differences
were only statistically significant in Puerto Maldonado (p,0.01).
In Iquitos no significant differences were observed between sexes
for DENV or OROV (Table 7). DENV infection was significantly
more common among participants younger than 15 in Iquitos
(p=0.005); however, this effect was only observed during the
earlier years of the study (2002 and 2003 in particular). OROV
infection in Iquitos was significantly more common among age
groups 15 or older (p=0.007). For the 30–44 year old age group,
MAYV infection was significantly more common than for
participants younger than 15 (Table 7).
The health centers in the Iquitos area included in this study
were predominantly public clinics and hospitals located within the
urban area of the city (n=8), although the study was also
conducted in three military clinics located within the urban area
Table 6. Yearly incidence rates of arboviral diseases in
Iquitos, Peru, per 100,000 residents.
2001 2002 2003 2004 2005 2006 2007 Average
All Febrile Cases 519.5 1213.2 591.9 1277.1 799.9 779.6 645.7 855.9
DENV 10.4 554.0 83.1 498.0 242.5 294.3 231.4 274.7
VEEV 16.2 16.1 14.2 25.5 30.7 58.2 24.8 28.1
MAYV 2.3 6.9 5.1 10.0 9.3 20.1 3.8 8.5
OROV 0.0 4.0 3.4 17.7 27.4 41.9 3.8 14.3
Group C viruses 1.2 2.9 5.1 30.4 33.5 12.0 11.9 14.2
The first year (2000) is excluded as the study did not start until mid-way through
the year.
doi:10.1371/journal.pntd.0000787.t006
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mately five and ten kilometers outside the city limits. The majority
of participants in the Iquitos area were recruited in the urban
clinics (79.6%), while 10.6% and 9.8% were recruited at the two
rural clinics and three military clinics, respectively. Using the
different categories of clinics as a proxy for potential differences in
arbovirus exposure, we compared the relative prevalence of
arboviruses among those reporting to the urban, rural, or military
clinics. DENV infection was far more common in participants
reporting to the urban clinics than rural clinics, whereas VEEV
(p=0.018), MAYV (p,0.001), and Group C viruses (p,0.001)
were more common among those reporting to the rural clinics. For
OROV infection there was no statistically significant differences
among the types of health centers (Table 7).
Participants were recruited year-round, with a peak in
December that was largely due to DENV transmission
(Figure 3A). Transmission of the arboviruses peaked during
different months of the year. Over the course of the study, DENV
transmission was most common between October and December
with lowest levels between June and August (Figure 3A).
Alphavirus transmission was highest between February and July
(Figure 3B), with reduced transmission during the second half of
the year, while the highest percentage of Group C virus cases was
observed between December and February (Figure 3C).
Discussion
Tropical areas, with year-round hot and humid conditions, are
particularly well-suited for maintaining arboviruses with both
current public health importance as well as the potential to emerge
as significant human pathogens [4]. Therefore in this study we
focused on arbovirus transmission in tropical regions of four
countries in South America. Our data demonstrate that
arboviruses are a common cause of human febrile illness in these
sites in South America, accounting for greater than 30% of the
febrile episodes analyzed. Importantly, arbovirus-associated dis-
ease was not restricted to DENV in most of the locations studied.
The other arboviruses identified, including VEEV, MAYV, and
OROV, in total were associated with approximately 8% of febrile
episodes. Our study has provided source material for various
phylogenetic analyses [12,14,19,23,26] and will provide important
baseline data for monitoring changes in arbovirus ecology,
epidemiology, and genetics.
There were several significant limitations to our study. First,
with the exception of Peru, the number of study sites in the other
countries was quite limited. Even in Peru, it is unclear whether
these results are indicative of arbovirus circulation in other regions
of the country. Another shortcoming was the focus on arboviruses.
While clearly these are important pathogens in the tropical
rainforest regions, along the desert coast (Piura) and in the
highlands (Cusco), other types of pathogens will need to be given
greater consideration. Another limitation of our study design is the
passive surveillance strategy employed. Clinic-based surveillance is
likely to significantly underestimate true arbovirus circulation, as
those with milder disease manifestations are less likely to visit a
health center. In studies of DENV transmission in Iquitos we have
observed that incidence rates calculated from community-based
active surveillance are several times higher than those calculated
based on passive surveillance (TJK, ACM, and BMF, unpublished
results). Accordingly the incidence rates presented here should be
interpreted carefully and considered a conservative estimate of the
true number of febrile episodes caused by each virus. Another
shortcoming of clinic-based surveillance is the difficulty of
extrapolating the data to the entire population. As we show here
in Iquitos, those who present to the health centers and those that
are willing to participate in these studies are often not fully
representative of the population at-large, which may lead to biases
in age-dependent incidence rates. In addition, with the exception
of Iquitos, we did not collect sufficient data from non-participants
to fully contextualize these results. Our data suggest that malaria
may contribute to approximately 30% of acute febrile illnesses in
Iquitos, a figure that would not be apparent based solely on those
who enrolled in the study. One advantage of clinic-based passive
surveillance is expanded geographic coverage and more limited
costs relative to other surveillance strategies, which is critically
important when studying the relatively obscure arboviruses
described here. Only through the large number of participants
presented here were we able to detect sufficient cases of VEEV,
MAYV, and OROV for further epidemiological analysis.
Over the course of the study, DENV serotypes were by far the
most common arboviruses associated with febrile disease,
accounting for 26% of febrile participants. DENV serotypes have
Table 7. Association between arbovirus infection and demographic variables in Iquitos, Peru, 2000–2007.
Variable Category Total DENV VEEV MAYV OROV Group C viruses
No. (%) No. (% pos) No. (% pos) No. (% pos) No. (% pos) No. (% pos)
Sex Male 5519 (51.4) 1764 (32.2) 206 (3.7)* 71 (1.3)* 94 (1.7) 103 (1.9)
Female 5220 (48.6) 1683 (32.0) 147 (2.8) 36 (0.7) 86 (1.6) 75 (1.4)
Age group ,15 2175 (20.2) 751 (34.5)* 61 (2.8) 15 (0.7) 21 (1.0)* 27 (1.2)
(yrs) 15–29 4959 (46.2) 1557 (31.4) 156 (3.1) 45 (0.9) 80 (1.6) 81 (1.6)
30–44 2311 (21.5) 748 (32.4) 95 (4.1) 28 (1.2) 54 (2.3) 47 (2.0)
45+ 1290 (12.0) 389 (30.2) 41 (3.2) 19 (1.5) 25 (1.9) 23 (1.8)
Clinic Urban 8552 (79.6) 3080 (36.0)** 271 (3.2)* 70 (0.8)** 139 (1.6) 128 (1.5)**
Military 1049 (9.8) 291 (27.7) 29 (2.8) 16 (1.5) 23 (2.2) 15 (1.4)
Rural 1138 (10.6) 76 (6.7) 53 (4.7) 21 (1.8) 18 (1.6) 35 (3.1)
*p,0.05;
**p,0.001.
For the Total column, numbers in parentheses represent the distribution of each variable within the category. For each individual arbovirus the numbers in parentheses
represent the percent of participants within each variable category that were positive for the selected arboviruses.
doi:10.1371/journal.pntd.0000787.t007
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the point that nearly a million cases of dengue fever are reported
every year in Latin America, along with thousands of cases of
more severe disease that may lead to hemorrhagic manifestations
and death [27,28]. Here we demonstrate that DENV-3 (previously
identified as subtype III [26]) was the predominant serotype in the
region between 2001–2007, although we also observed significant
DENV-1 and DENV-2 transmission in certain regions. Not
surprisingly DENV circulation was found to be more region-
dependent than country-dependent. Specifically, Tumbes and
Piura along the coast of northern Peru share common trends with
Guayaquil in Ecuador (Figure 2A), while DENV circulation in
Puerto Maldonado in southern Peru is more closely tied to trends
observed in Bolivia (Figure 2C). More recently we observed that a
Figure 3. Monthly distribution of participants with arbovirus infection in Iquitos, Peru, 2000–2007. Data are represented as the percent
of participants with date of disease onset in each month. The monthly distribution of all participants is shown in (A), while participants with recent
infection by a DENV, an alphavirus, or an orthobunyavirus are shown in (A), (B), and (C), respectively.
doi:10.1371/journal.pntd.0000787.g003
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(2006), then coastal Peru (2007), before spreading to the tropical
rainforests of northeastern Peru (Iquitos and Yurimaguas; 2008)
[23]. As multiple serotypes have been circulating in the region
severe disease resulting from heterologous secondary infection is
increasingly likely to occur [27,29]. In this study we did not
distinguish between primary and secondary infection, and thus
further analysis will be needed to identify the genotypes [30] and
prior DENV immune status associated with more severe disease
outcomes in the region. Regardless, the data described here will
provide a springboard for future studies of regional DENV
maintenance and dispersion patterns [31] as well as analysis of
genetic adaptation and selective pressures.
Other than DENV, the only other flavivirus isolated was YFV.
One well-documented hindrance to study flavivirus is the cross-
reaction observed among even disparate species [32,33]. Similarly
here we observed significant cross-reaction between DENV and
YFV antigen in serum from patients with defined DENV infection,
thus there is a possibility that some of the cases have been
misclassified. For YFV, we only considered those instances where
there was no DENV IgM detected. Furthermore, there was a
strong correlation between participants reporting recent YF
vaccination and having YFV-reactive IgM, suggesting that these
results were not due to cross-reactivity with other flaviviruses
circulating in South America. Low grade fever and headache are
not uncommon outcomes within the two weeks following YF
vaccination [34,35], so it is possible that these cases are due to the
vaccination. It should be noted, however, that flavivirus IgM can
be long-lived [32], and thus many of these febrile episodes
classified as ‘‘YFV infection’’ may not represent the true etiologic
agent. In addition, in our study we only rarely observed severe
disease associated with YFV-reactive IgM, suggesting that these
cases largely do not reflect natural infection and thus should be
interpreted with caution.
In addition to DENV and YFV, there are other flaviviruses
circulating in the region that need to be considered, including
WNV, Rocio virus (ROCV), Ilheus virus (ILHV), and St. Louis
encephalitis virus (SLEV). These flaviviruses have been isolated
either from mosquitoes [36], birds [37], or mammals [38],
including humans [39,40], in parts of South America. More
closely related to our study areas, ILHV has been isolated from a
febrile patient in Ecuador [41], and ILHV and SLEV have been
isolated from mosquitoes in Iquitos [36], clearly demonstrating
that these viruses are circulating near human populations in the
region. None of these viruses were isolated from participants in our
study, suggesting that human infection is uncommon. However, in
a preliminary survey of a subset of our participants we have
identified cases where ROCV, ILHV, SLEV, or WNV IgM was
detected, with no reactivity with DENV or YFV antigen (data not
shown), with confirmation by virus neutralization assay, consid-
ered the most specific tool for flavivirus serology [42]. Overall, the
cross-reactivity reported here and elsewhere [32] and the longevity
of flavivirus IgM underscore the complications of flavivirus
serodiagnosis, which represents a great hindrance for epidemio-
logical surveillance.
The most common Alphavirus species identified were VEEV and
MAYV. Scant evidence for human infection with EEEV was
identified, consistent with previous reports [43], despite evidence
of EEEV circulation in mosquitoes near Iquitos [36,44], for
example. In light of the recent emergence of another alphavirus,
CHIKV, in the Indian Ocean region, VEEV and MAYV
represent interesting cases to consider with regards to potential
for urban emergence. In laboratory studies Aedes spp., the primary
vectors for DENV, have been shown to be a competent vector for
VEEV [45] and MAYV [46]. Even without adapting to human-
Aedes-human cycles, epizootic VEEV subtypes have been associ-
ated with large outbreaks of human disease across South America
[6]. As recently as 1995 a VEEV outbreak was responsible for
nearly 100,000 febrile cases in Venezuela and Colombia [47,48].
While the VEEV strains isolated in our study all belong to enzootic
genotypes of the virus complex [12,14,24], genetic studies have
demonstrated that enzootic and epizootic subtypes are closely
related. A modest number of amino acid changes can alter the
viral phenotype dramatically, converting an enzootic strain to an
epizootic strain [49–52]. Similarly, amino acid variants in the
CHIKV E1 protein have been associated with increased epidemic
potential [53–55]. Several other factors further suggest that
potential for neotropical alphavirus emergence is high. In the
Iquitos area, while we found that VEEV was more commonly
associated with rural clinics (Table 7), many of the participants
with confirmed VEEV infection lived within the city and did not
report leaving the urban area during the month prior to the febrile
illness [24](data not shown). This data is corroborated by a
previous study of healthy participants, in which we found that
nearly 25% of the urban population carries VEEV-neutralizing
antibodies [24]. In addition, based on data collected through this
program the geographic range of MAYV and VEEV is wider than
had been previously demonstrated, extending to southern Peru
and Bolivia [14,19]. Taken together these factors suggest that the
potential establishment of the neotropical alphaviruses as urban
pathogens should be closely monitored.
In addition to the flaviviruses and alphaviruses, orthobunya-
viruses were significant sources of febrile illness in the study,
accounting for 2.5% of febrile episodes analyzed. While all
orthobunyavirus isolates came from patients in Peruvian rainforest
sites during the course of this study, we did find serological
evidence for OROV and Group C viruses in Ecuador and Bolivia.
More recently (2008) we have definitively identified Group C
viruses in Bolivia, isolated from two participants in the
Cochabamba region (data not shown). Like VEEV and MAYV,
OROV is an interesting case study with regards to potential for
broader emergence. OROV has been associated with numerous
outbreaks in Brazil, infecting approximately 500,000 people in
South America over the past 45 years [56–58]. Two distinct
transmission cycles have been proposed, a poorly-defined sylvatic
cycle and an urban cycle where OROV is transmitted among
humans by the biting midge Culicoides paraensis [58,59]. In Iquitos,
we found that unlike the Group C viruses, VEEV, and MAYV,
evidence of recent OROV infection (based on both IgM and virus
isolation data) showed no significant bias towards rural clinics,
suggesting similar transmission levels between urban and rural
sites, consistent with results from an earlier survey of healthy
participants in the region [10]. This pattern may reflect a peri-
urban transmission cycle, as the majority of the OROV isolates
were detected in both the rural sites and an urban site located
towards the periphery of the city in 2005 and 2006 during a period
of markedly increased transmission (Table 6). OROV isolates from
previous Iquitos studies (prior to 1998) were found to belong to
lineage II, similar to strains associated with Brazilian OROV
outbreaks [56,60]. Future sequence analysis of the more recent
isolates described in this current study from Iquitos, Yurimaguas,
and Puerto Maldonado, will provide a more complete description
of OROV geographic and temporal genetic variability.
Considering the association of arboviral pathogens with human
disease and the potential for wider-scale emergence, disease
surveillance is an integral component of public health planning,
disease control, and analysis of potential intervention strategies.
Unfortunately, for the arboviruses described here syndromic
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and symptoms [5], particularly early in disease progression. As
with other reports [7,9], our study underscores the need for
laboratory-based support of febrile surveillance studies. Even
within our study other pathogens clearly need to be considered, as
the majority of febrile episodes in this study were not associated
with an arboviral etiology. In Iquitos past studies have linked both
Leptospira spp. and Rickettsia spp. with a significant percentage of
febrile illnesses [61–63]. To-date, solid data are lacking for the
other study sites included in this study, although our preliminary
results suggest that Leptospira spp. and Rickettsia spp. are common
human pathogens in these locations as well (TJK, unpublished
results). Admittedly our studies provide little in the way of
guidance for patient care but do point toward the need for the
development of pharmaceutical therapies for the treatment of a
variety of viral infections. In addition the development of rapid
and inexpensive diagnostic tools should be given high research
priority, particularly to distinguish arbovirus infection from other
pathogens where effective and inexpensive pharmaceutical
treatment is already available, such as for Rickettsia spp. and
Leptospira spp.
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